Tandem Meetings 2023 | The use of chemotherapy in R/R Hodgkin and non-Hodgkin lymphomas
Sanjal Desai, MD, University of Minnesota Medical School, Minneapolis, MN, compares and contrasts the use of chemotherapy in patients with relapsed/refractory (R/R) Hodgkin and non-Hodgkin lymphomas (HL; NHL). While patients with HL are increasingly being treated with novel regimens using less chemotherapy, including checkpoint inhibitors and brentuximab-based treatments, patients with NHL are usually treated with R-ICE and R-DHAP chemotherapy prior to autologous transplantation. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
